Asiyla Gum Company

Asylia Therapeutics is a biotechnology company focused on developing a pipeline of antibodies that target a novel extracellular protein folding mechanism to treat cancer and autoimmune diseases. The company's lead programs are centered around targeting extracellular Heat Shock Protein 70 (HSP70), which plays a critical role in immune evasion and tumor survival. By neutralizing extracellular HSP70, Asylia aims to restore the immune system's ability to recognize and destroy cancer cells. The company was founded by world-renowned oncology researchers and is leveraging its proprietary platform to advance multiple therapeutic candidates toward clinical trials.